Isradipine

Quick links to important sections

Isradipine

Selected form

Treatment option: Hypertension

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isradipine

Property Description
Active Ingredient Isradipine (INN)
Form Oral Capsules (Immediate-release and Controlled-release)
Pharmacological Class Calcium Channel Blocker (Dihydropyridine)
General Purpose Cardiovascular support, Vascular resistance reduction
Origin Synthetic, Pyridine derivative

What Type of Medicine is Isradipine?

Isradipine is a synthetic pharmaceutical agent classified as a Calcium Channel Blocker, often referred to as a Calcium Antagonist. This medicine belongs specifically to the dihydropyridine derivative class, distinguishing it as a second-generation compound primarily used as a cardiovascular agent. Isradipine is characterized by a potent, selective effect on the smooth muscle of blood vessels. This means the medicine is specifically designed to act on blood vessels rather than having a primary effect on heart rhythm. Isradipine is noted for its high vascular selectivity, a feature clinically recognized as a key differentiator from non-dihydropyridine calcium antagonists.

Active Ingredient and Available Forms

The active ingredient in this medication is Isradipine, a single-ingredient compound formulated for oral administration. The drug is most commonly supplied in capsule form, which includes both immediate-release capsules and controlled-release formulations that are designed to deliver the medicine steadily over an extended duration. The use of controlled-release formulations aids in achieving consistent therapeutic effects throughout the day. This steady delivery helps maintain the desired effect on blood vessels consistently. As an INN compound, Isradipine is available generically and under various trade names, consistently presented as a prescription-only medicine.

What is the General Purpose of Isradipine?

The general purpose of Isradipine is to support the cardiovascular system by promoting smoother blood flow and reducing the resistance of blood vessels. This beneficial action is achieved because the drug selectively induces vasodilation, which is the widening of the arteries. By relaxing the muscle walls of the blood vessels, Isradipine decreases the overall resistance that the heart must overcome, thereby lowering the pressure within the circulatory system and reducing vascular strain, which is the definition of an antihypertensive action.

Regulatory References

  1. Isradipine: LiverTox - NIH
  2. Isradipine Capsules DailyMed Label (NIH/FDA)

What side effects are possible with Isradipine?

Possible Side Effects and Safety Information

The official safety profile for Isradipine is structured by government regulatory bodies to define expected, common, and serious adverse reactions based on clinical trial data. Many of the most frequently reported adverse events are linked to the drug's primary action as a vasodilator (widening of blood vessels), and the frequency of several effects is documented to increase at higher dosages (above 10 mg/day).

Frequency-Classified Adverse Reactions

The adverse reactions listed in regulatory documents are grouped by frequency and physiological system. Effects classified as More Common (or common) often include headache, flushing (redness or warmth), edema (swelling, often in the feet or lower legs), and dizziness. Less common events reported across the Gastrointestinal System and Cardiovascular System may include nausea, vomiting, chest pain, and changes in heart rate such as tachycardia.

Serious Adverse Reactions and Safety Constraints

While rare, the official label documents serious adverse reactions, which include events such as symptomatic hypotension (a significant drop in blood pressure with symptoms), angioedema (swelling of the face, lips, or tongue), and reports of Myocardial Infarction (heart attack). High-level safety notes indicate that coadministration with certain drugs that inhibit metabolism, such as Cimetidine, can increase the concentration of Isradipine, thereby increasing the potential for adverse effects.

Population-Specific Safety Considerations

Safety data emphasizes specific considerations for certain patient groups. Individuals with Hepatic Impairment (liver problems) may require careful dosage adjustment or titration. Similarly, the drug should be used with caution in patients with Congestive Heart Failure due to the potential for the medication to worsen the underlying condition, as noted in professional monographs. Older adults may also require attention due to the higher likelihood of pre-existing liver or kidney impairment.

Overdose and Emergency Response

Isradipine Overdose and when to seek help

Category Official Regulatory Statement
Documented overdose presentations: Manifestations typically involve severe cardiovascular changes, including Transient Hypotension, Sinus Tachycardia, Bradycardia, and Atrioventricular (AV) Nodal Block. Other listed signs are Lethargy, Confusion, Breathing Difficulty, and Hyperglycemia.
Physiological systems affected (as stated in label): Primary systems affected are the Cardiovascular System (potential for shock) and the Central Nervous System (potential for altered mental status).
Dose-related or exposure-related factors (if applicable): Toxicity symptoms may be delayed up to 16 hours following ingestion of Controlled-Release formulations, necessitating prolonged observation.
Population-specific overdose notes (if applicable): Severe outcomes are more likely with co-ingestion of other cardioactive drugs or in patients with certain pre-existing cardiac conditions.
Emergency-response statements (as written in official documents): Management is defined as Symptomatic and Supportive, as no specific antidote is known. Procedures may include Activated Charcoal or Whole Bowel Irrigation and advanced supportive measures like IV Calcium Salts and Vasopressors.
When immediate medical help is required (label-derived phrasing only): Immediate medical help must be sought for any suspected overdose. Emergency services must be called right away if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.
Category Official Regulatory Statement
Severity classification (as defined in official documents): The overdose carries the potential for life-threatening consequences, including Shock and Cardiac Arrest.
Regulatory basis (EMA / FDA / etc.): Information is derived from the official prescribing information and patient guidance from government health authorities.
Overdose-context constraints (as defined in official documents): Continuous hospital monitoring is required for all symptomatic patients and those who have ingested sustained-release preparations.

Resulting overdose structure

Official overdose statements:

  • Overdose may present with severe cardiovascular signs, including profound hypotension, sinus tachycardia, or bradycardia, which can progress to shock and cardiac arrest.
  • The official documents mandate calling emergency services immediately if the individual is unresponsive, seizing, or having trouble breathing, as these are signs of life-threatening toxicity.
  • Management focuses on supportive treatment, including continuous monitoring, IV fluid support, and potential administration of agents like calcium salts and vasopressors, since no specific antidote is available.
  • The onset of serious symptoms can be significantly delayed, requiring hospital observation for up to 16 hours following the ingestion of controlled-release formulations.

Connection to the overall overdose profile (2–4 sentences): The regulatory documents define the Isradipine overdose profile based on documented severe cardiovascular and CNS manifestations. This structure mandates that any suspected overdose requires immediately seeking medical help due to the potential for life-threatening outcomes like cardiac arrest. The label dictates a purely supportive treatment strategy and highlights the necessity for prolonged observation due to the potential for delayed toxicity.

Therapeutic Uses of Isradipine

Isradipine is a medication commonly used for the management of high blood pressure, a condition also known as hypertension. Its main use is to address this common condition. Isradipine is considered relevant in conditions presenting with systemic or localized discomfort.

The medication is commonly used across conditions presenting with acute episodes. It helps ease symptoms related to heightened physiological activity.

Quick Fact: Relief for Symptoms related to heightened physiological activity

By easing the overall symptom load, isradipine contributes to improved comfort during periods of heightened symptoms. The medication may assist with easing symptoms related to heightened physiological activity. It supports patients during difficult episodes by easing distress. The relevant therapeutic area involves the management of hypertension. The use of this treatment is applicable within clinical settings that involve acute or disruptive symptom patterns, and assists with maintaining functional stability.

The treatment may assist by providing support that helps ease the overall symptom burden.

Isradipine may be part of symptomatic management for conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations. It helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Isradipine

Isradipine eligibility is determined by specific regulatory classifications regarding patient health status and age. This information reflects requirements stated in official government prescribing documents, such as those from the FDA and EMA.


Absolute Exclusion (Contraindications)

Classification Who Must Not Use Isradipine
Hypersensitivity Individuals with a known allergy or hypersensitivity to isradipine or any component of the formulation.

Restricted or Conditional Use

Population/Condition Regulatory Requirement
Pediatric Patients Safety and effectiveness have not been established in children and adolescents; use is not recommended.
Hepatic or Renal Impairment Use requires caution and close monitoring; dose adjustment may be necessary due to altered drug clearance.
Pregnancy (Category C) Use is conditional; permitted only if the potential benefit justifies the potential risk to the fetus.
Lactation Discontinue nursing or discontinue the drug due to unknown excretion into human milk and potential risk to the infant.

Note: Older adults may also require caution and potential dose adjustment due to the higher likelihood of existing organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Isradipine's interaction profile is primarily defined by its reliance on the CYP3A4 metabolic pathway and the risk of additive pharmacodynamic effects.

Formally Documented Restrictions

Co-administration with strong CYP3A4 inducers is either contraindicated or strongly advised against by regulatory authorities. For example, co-administering Isradipine with Rifampicin is documented to reduce Isradipine plasma concentrations to below detectable limits, effectively abolishing its expected effect. Other strong enzyme-inducing drugs, such as certain anticonvulsants (e.g., Carbamazepine, Phenobarbital, Phenytoin), are also associated with markedly reduced Isradipine levels.

Conversely, medicines that inhibit CYP enzymes, such as Cimetidine, have been officially documented to increase Isradipine exposure, raising the mean peak plasma concentration (Cmax) and Area Under the Curve (AUC).

Pharmacodynamic and Substance Interactions

There is a documented risk of additive hypotensive effects when Isradipine is combined with other blood pressure-lowering agents or alcohol. The official profile also cautions against consuming Grapefruit Juice, which may increase Isradipine’s bioavailability and subsequent blood levels. Furthermore, a specific caution exists regarding the use of Beta-Blockers alongside Isradipine during Fentanyl-based anesthesia due to the risk of severe hypotension.

For specific patient populations, the interaction profile may be heightened in cases of hepatic impairment due to the slower removal of the medicine from the body.

Mechanism of Action

Isradipine's mechanism of action centers on its selective interaction with the structures governing vascular contractility, exerting its effect through two primary mechanistic domains.

Modulation of L-Type Calcium Channels

Isradipine, a dihydropyridine class calcium channel blocker, acts as a selective inhibitor of L-type voltage-gated calcium channels (CaV1.2). These channels are predominantly located on the membranes of arterial vascular smooth muscle cells. The drug binds to and stabilizes the channel in an inactive conformation, which significantly reduces the influx of extracellular calcium ions (Ca^2+) into the smooth muscle cytoplasm. This inhibition disrupts the initial molecular step required for excitation-contraction coupling.


Regulation of Vascular Tone

By decreasing the intracellular calcium concentration, Isradipine modifies the key molecular cascade required for muscle contraction. The reduced calcium availability prevents the activation of the myosin light chain kinase (MLCK), leading to a subsequent reduction in myosin phosphorylation. The resulting cellular consequence is the relaxation of the arterial smooth muscle (vasodilation), which decreases peripheral vascular resistance and lowers arterial blood pressure.

Dosage and Administration Information

How Isradipine is Used

Isradipine is administered exclusively via the oral route for long-term management, utilizing two main formulations: immediate-release (IR) capsules and controlled-release (CR/ER) tablets. The administration schedule is dependent on the formulation, with IR capsules typically taken twice daily (b.i.d.) and CR/ER tablets taken once daily (q.d.).

Administration is generally performed without regard to meals, allowing for consistent dosing flexibility.

Official Dosing and Titration

Treatment typically initiates with a low dose, such as 2.5 mg b.i.d. for IR capsules or 5 mg q.d. for CR/ER tablets. Dosage adjustments, if required, must be made incrementally in steps of 5 mg total daily dose, and these increases should occur only after a period of 2 to 4 weeks has elapsed. The maximum recommended daily dose for both formulations is 20 mg.

Form-Specific Handling

The controlled-release tablets are designed to be swallowed whole and must not be broken, crushed, or chewed, as this compromises the intended extended-release properties. Information indicates that the use of controlled-release tablets requires caution in patients with severe gastrointestinal narrowing, a procedural constraint related to the nondeformable nature of the tablet.

Population-Based Usage

For older adults, the initial starting dose is often the lowest available strength, and slower dosage escalation is often advised. While no initial dose adjustment is explicitly recommended for patients with renal or hepatic impairment, careful and slower titration is generally advised, particularly due to reduced drug clearance in hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Isradipine


Evidence for Use in Managing Essential Hypertension

The primary body of research for Isradipine was evaluated in essential hypertension, or high blood pressure. These studies are mostly composed of randomized controlled trials (RCTs). Researchers primarily monitored systolic and diastolic blood pressure (BP), which are outcomes monitoring physiological strain or stress. Findings describe patterns related to blood pressure measurements observed in the groups receiving the medicine compared to those receiving a placebo, with research exploring the rate at which measurements related to blood pressure normalization were noted.

Despite the volume of RCTs, there is limited information for long-term outcomes regarding major cardiovascular events like stroke or heart attack over many years. The key clinical trials focused on blood pressure reduction over a matter of weeks or months. This means that the research does not determine whether an individual will show different long-term cardiovascular outcomes.


Research in Investigational Contexts (Neurological Conditions)

Beyond its use for high blood pressure, Isradipine was studied for other contexts. Specifically, it was evaluated in large, extended-duration, Phase 3 randomized controlled trials to explore its potential role in conditions like early-stage Parkinson's disease (PD). This long-term research examined adults recently diagnosed with PD.

The primary outcome monitored was the change in measurements of outcomes reflecting daily functioning or activity level and clinical progression. Research describes that the overall clinical progression of Parkinson's disease, as measured by the primary outcome scale, showed similar patterns between the group receiving the medicine and the placebo group. Certainty remains low in this investigational context; the major Phase 3 trial did not show a difference in the primary measure of disease progression compared to placebo.


What Is Still Uncertain About Isradipine Research

The evidence highlights what is known — and what is still uncertain — about the medicine. Long-term cardiovascular outcomes are not fully established. The existing research primarily documents effects on blood pressure over short- to intermediate-term follow-up durations. Furthermore, the findings for its use in early-stage Parkinson's disease were mixed in the large Phase 3 trial. Evidence quality varies across studies, and data for certain groups, such as children or pregnant populations, remain insufficient in the core regulatory record.

Frequently Asked Questions (FAQ)

Common questions about Isradipine (FAQ)


Q: How quickly should I expect Isradipine to start working?

A: Studies and official information indicate that blood pressure response varies between individuals. To allow time for the medication to stabilize, healthcare providers typically wait two to four weeks before evaluating the full effect of a given dose. The full therapeutic effect is typically assessed by healthcare providers after this period.

Q: Is a slight headache normal when starting Isradipine?

A: Yes, headache is listed as a common side effect of isradipine in the official product safety information. This effect is often linked to the way the medication works to widen blood vessels (vasodilation). Persistent or severe headaches should be discussed with a healthcare provider.

Q: Are there any serious side effects I should be aware of with Isradipine?

A: The official labeling documents serious, but rare, side effects that require immediate medical attention. These include angioedema, which is a severe swelling of the face, lips, tongue, or throat, and symptomatic hypotension, which is a significant drop in blood pressure causing severe dizziness or fainting. A severe adverse reaction requires immediate medical attention.

Q: What over-the-counter medications should be avoided while taking Isradipine?

A: Official drug interaction information cautions about potential interactions with certain drugs metabolized by the CYP3A4 pathway in the liver. Additionally, patient resources sometimes warn that some common over-the-counter medications, like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), could reduce the blood pressure-lowering effect. It is important to inform a healthcare provider of all medications and supplements being taken.

Q: Is Isradipine commonly used in people with kidney problems?

A: Isradipine should be used with caution in patients who have kidney problems. Official labeling states that the drug's effects may be increased in these individuals because the body may remove the medicine more slowly. Close monitoring by a healthcare provider may be required.

Q: Is there clinical research showing Isradipine's effectiveness?

A: Yes, isradipine's effectiveness for treating hypertension (high blood pressure) was established through controlled clinical trials. These studies demonstrated that the drug was effective at reducing systolic and diastolic blood pressure measurements compared to a placebo (an inactive substance).

Q: Does Isradipine affect sleep?

A: The official safety list does not explicitly list insomnia as a common side effect. However, the product information does note effects on the central nervous system, such as dizziness and excessive tiredness, which could potentially impact the quality of sleep. Persistent sleep changes should be reviewed with a healthcare provider.

Q: Is it possible for Isradipine to stop working after a while?

A: Official labeling notes that taking isradipine with certain strong enzyme-inducing drugs, like rifampicin, can significantly lower its blood levels, potentially abolishing its expected effect. Official product information does not indicate a loss of effectiveness (tolerance) over time in stable patients taking the drug alone.

Q: Are there any monitoring tests needed while taking Isradipine?

A: Official safety information advises that a patient’s progress should be checked at regular intervals. This is to monitor the effectiveness of the treatment and to check for unwanted effects, particularly low blood pressure. The need for specific laboratory tests is determined by the healthcare provider.

Q: Does Isradipine need to be taken long-term?

A: Isradipine is used to help control high blood pressure, not to cure it entirely. The medicine is generally used for long-term management of blood pressure to reduce the risk of serious complications, and a long-term regimen may be required.

Q: Is Isradipine used for conditions other than just hypertension?

A: Isradipine is officially indicated and approved only for the treatment of hypertension (high blood pressure). Although it may be studied or used by healthcare providers for other conditions, its primary, approved purpose is to lower blood pressure.

Q: Is it okay to drive or operate machinery while on Isradipine?

A: Warnings in patient information advise caution regarding driving or operating heavy machinery. Since side effects like dizziness or lightheadedness are possible, activities requiring full alertness should be avoided until the user is aware of how the medication affects them.

Q: Does Isradipine affect heart rate?

A: Yes, isradipine can affect heart rate. The official safety profile lists a fast heartbeat, known as tachycardia, as a less common side effect. Significant changes in heart rate or rhythm should be reviewed with a healthcare provider.

Q: Are there any specific dietary restrictions when taking Isradipine?

A: The most important restriction noted in official drug interaction information is to avoid or significantly limit the consumption of grapefruit and grapefruit juice. These products can interfere with the way the body processes the medication, potentially increasing the drug’s blood levels and the risk of side effects.

Q: What happens if a dose of Isradipine is missed?

A: Official guidance on a missed dose states to take it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. It is important not to take a double dose to compensate for a missed dose.

Q: Is Isradipine ever used in combination with ACE inhibitors?

A: Isradipine is officially approved to be used either alone or in combination with other blood pressure medications, such as thiazide diuretics. The official labeling does not include restrictions against combining it with other common blood pressure agents like ACE inhibitors.

Q: Is Isradipine a sustained-release or extended-release medication?

A: Isradipine is available in two distinct formulations. It comes as immediate-release capsules and as extended-release (or controlled-release) tablets. The extended-release form is specifically designed to provide a steady effect over a longer period of time.

Q: What are the signs of a potential allergic reaction to Isradipine?

A: Signs of a potential severe allergic reaction include hives or rash, swelling of the face, lips, tongue, or eyes, and difficulty breathing or swallowing. Any signs of a potential allergic reaction require prompt reporting to a medical professional.

Q: How is Isradipine eliminated from the body?

A: Isradipine is extensively processed, or metabolized, by the liver. The drug and its resulting inactive compounds are then eliminated from the body primarily through the urine (renal excretion) and in the feces.

How should Isradipine be stored and disposed of?

How to Store and Dispose of Isradipine

Isradipine (capsules) must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Requirement Details
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Prohibited Conditions Keep from freezing and excess heat. Protect from moisture and humidity.
Packaging Store in the original container, keeping the container tightly closed and light-resistant.
Child Safety Mandatory instruction to keep Isradipine out of the reach of children.

Disposal: Unneeded or expired Isradipine should not be flushed down the toilet or poured into a drain. Disposal must follow official instructions, such as utilizing a medicine take-back program or consulting a pharmacist for guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Isradipine found in:

A-Z Index: